Safer CAR Ts & world’s first TIL: BioCentury’s latest podcast
BioCentury
by
5h ago
FEB 20, 2024 | 6:18 PM PST | BIOCENTURY | PRODUCT DEVELOPMENT SAFER CAR TS & WORLD’S FIRST TIL: BIOCENTURY’S LATEST PODCAST BY Plus: translational highlights and Sarepta’s path to a gene therapy approval https://www.biocentury.com/article/651488/safer-car-ts-world-s-first-til-biocentury-s-latest-podcast© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Rare disease spotlight: treating a facial muscular dystrophy at its root
BioCentury
by
5h ago
FEB 20, 2024 | 5:18 PM PST | BIOCENTURY | PRODUCT DEVELOPMENT RARE DISEASE SPOTLIGHT: TREATING A FACIAL MUSCULAR DYSTROPHY AT ITS ROOT BY As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic causehttps://www.biocentury.com/article/651378/rare-disease-spotlight-treating-a-facial-muscular-dystrophy-at-its-root© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Phil Pang exiting Vir as CMO
BioCentury
by
5h ago
FEB 20, 2024 | 5:03 PM PST | BIOCENTURY | MANAGEMENT TRACKS PHIL PANG EXITING VIR AS CMO BY Plus: Arshad Khanani named chief medical adviser at Opthea and Smart Immune names a chairhttps://www.biocentury.com/article/651491/phil-pang-exiting-vir-as-cmo© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Four pharma joining to present case against IRA
BioCentury
by
5h ago
FEB 20, 2024 | 4:16 PM PST | BIOCENTURY | POLITICS, POLICY & LAW FOUR PHARMA JOINING TO PRESENT CASE AGAINST IRA BY BMS, J&J, Novartis, Novo Nordisk cooperating in legal casehttps://www.biocentury.com/article/651494/four-pharma-joining-to-present-case-against-ira© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
BioCentury
by
5h ago
FEB 20, 2024 | 4:11 PM PST | BIOCENTURY | DEALS DEAL REPORT: ASTELLAS TAPS KELONIA FOR CAR TS, AURINIA FAILS TO FIND BUYER, AND MORE BY Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and morehttps://www.biocentury.com/article/651487/deal-report-astellas-taps-kelonia-for-car-ts-aurinia-fails-to-find-buyer-and-more© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Recent deals map out AbbVie’s future as Gonzalez hands CEO job to Michael
BioCentury
by
5h ago
FEB 20, 2024 | 2:53 PM PST | BIOCENTURY | MANAGEMENT TRACKS RECENT DEALS MAP OUT ABBVIE’S FUTURE AS GONZALEZ HANDS CEO JOB TO MICHAEL BY COO’s rise to top role closely follows deals designed for long-term growth, while pair of immunology drugs help offset Humira’s shortfallhttps://www.biocentury.com/article/651485/recent-deals-map-out-abbvie-s-future-as-gonzalez-hands-ceo-job-to-michael© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
EraCal: fishing for new obesity targets
BioCentury
by
5h ago
FEB 20, 2024 | 1:03 PM PST | BIOCENTURY | EMERGING COMPANY PROFILE ERACAL: FISHING FOR NEW OBESITY TARGETS BY Swiss company’s zebrafish platform identifies new appetite suppressant targets without unwanted adverse effectshttps://www.biocentury.com/article/651444/eracal-fishing-for-new-obesity-targets© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Science spotlight: a germinal center B cell-activating adjuvant, peptide-conjugated CARs and more
BioCentury
by
4d ago
FEB 16, 2024 | 6:34 PM PST | BIOCENTURY | DISCOVERY & TRANSLATION SCIENCE SPOTLIGHT: A GERMINAL CENTER B CELL-ACTIVATING ADJUVANT, PEPTIDE-CONJUGATED CARS AND MORE BY BioCentury’s roundup of translational innovationshttps://www.biocentury.com/article/651474/science-spotlight-a-germinal-center-b-cell-activating-adjuvant-peptide-conjugated-cars-and-more© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
With eyes on manufacturing, Iovance’s TIL therapy reaches long-awaited, world-first approval 
BioCentury
by
4d ago
FEB 16, 2024 | 6:10 PM PST | BIOCENTURY | REGULATION WITH EYES ON MANUFACTURING, IOVANCE’S TIL THERAPY REACHES LONG-AWAITED, WORLD-FIRST APPROVAL  BY Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’https://www.biocentury.com/article/651483/with-eyes-on-manufacturing-iovance-s-til-therapy-reaches-long-awaited-world-first-approval© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website
Agresta joining OnKure as CMO
BioCentury
by
4d ago
FEB 16, 2024 | 4:56 PM PST | BIOCENTURY | MANAGEMENT TRACKS AGRESTA JOINING ONKURE AS CMO BY Plus: Viridian hires Tousignant and an update from Ligandhttps://www.biocentury.com/article/651477/agresta-joining-onkure-as-cmo© 2024 BioCentury Inc. All Rights Reserved ..read more
Visit website

Follow BioCentury on FeedSpot

Continue with Google
Continue with Apple
OR